PMID- 1430114
OWN - NLM
STAT- MEDLINE
DCOM- 19921209
LR  - 20190918
IS  - 0048-0444 (Print)
IS  - 0048-0444 (Linking)
VI  - 59
IP  - 5
DP  - 1992 Oct
TI  - [A study to increase the therapeutic effects of adoptive immunotherapy in vivo. 
      Influence on the generation of lymphokine activated killer (LAK) cells and 
      therapeutic effects of LAK cells with anti-tumor drug (cyclophosphamide)].
PG  - 418-27
AB  - To enhance the effect of adoptive immunotherapy (AIT), we investigated the 
      induction and characteristics of lymphokine activated killer (LAK) cells and also 
      analyzed the combined effects of AIT with an antitumor drug (cyclophosphamide: 
      CPA) in mice models. LAK cells were generated from C57/BL/6 (B6) spleen cells. 
      The spleen cells were passed through a nylon wool column and cultured in 
      RPMI-1640 medium containing 10% FCS and 2 x 10(3) units of human recombinant IL-2 
      (hr IL-2) for up to 14 days. During this period, the time kinetic analyses of the 
      LAK cells' cytotoxicity and motility were performed. The cytotoxicities against 
      Lewis Lung Carcinoma (3LL), evaluated by standard 51Cr release assay, gradually 
      increased during the cultured period, and the motilities, determined by a 
      modified version of the Boyden chamber method, greatly increased within the first 
      7 days' incubation. Based on these in vitro findings, we examined the efficacy of 
      AIT alone or in combination with chemotherapy (CPA) in in vivo studies. AIT was 
      performed in the following way: LAK cells were intravenously infused and rIL-2 
      was intraperitoneally administered for 5 consecutive days following LAK cell 
      administration. CPA was intraperitoneally administered. The therapy protocols 
      were as follows. There were seven experimental groups. Group I; the mice were 
      infused with 3-day cultured LAK cells (3DLAKs) on the second day after tumor 
      inoculation (day 2). Group II; the mice were infused with 3DLAKs on day 5. Group 
      III; 10-day cultured LAK cells (10DLAKs) on day 2. Group IV; 10DLAKs on day 5. 
      Group V (AIT and CPA combination); AIT (10DLAKs) was started on day 5 followed by 
      CPA on day 10. Group VI; CPA was performed on day 5 followed by AIT (10DLAKs) on 
      day 10. Group VII; CPA was performed on day 5 without AIT. Each group consisted 
      on 15 mice. The therapeutic efficacies were evaluated by calculating the median 
      survival time of each group. The results of these experiments were as follows 
      (mean +/- SD); Group I's median survival time was 16.8 +/- 3.2 days, Group II 
      15.1 +/- 2.1 days, Group III 19.2 +/- 5.4 days, Group IV 16.1 +/- 4.8 days, Group 
      V 23 +/- 6.3 days, Group VI 32 +/- 8.4 days and Group VII 22 +/- 5.1 days. These 
      results suggested that the efficacy of AIT is closely related to the LAK cells' 
      cytotoxicity and motility. Although AIT alone in the advanced tumor bearing host 
      had a limited effect, combination with CPA improved it's efficacy.(ABSTRACT 
      TRUNCATED AT 400 WORDS)
FAU - Yoshimori, K
AU  - Yoshimori K
AD  - Fourth Department of Internal Medicine, Nippon Medical School.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Ika Daigaku Zasshi
JT  - Nihon Ika Daigaku zasshi
JID - 7505726
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Animals
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/*therapeutic use
MH  - *Immunotherapy, Adoptive
MH  - Interleukin-2/*therapeutic use
MH  - Killer Cells, Lymphokine-Activated/*transplantation
MH  - Mice
MH  - Neoplasms, Experimental/*therapy
MH  - Recombinant Proteins/therapeutic use
EDAT- 1992/10/01 00:00
MHDA- 1992/10/01 00:01
CRDT- 1992/10/01 00:00
PHST- 1992/10/01 00:00 [pubmed]
PHST- 1992/10/01 00:01 [medline]
PHST- 1992/10/01 00:00 [entrez]
AID - 10.1272/jnms1923.59.418 [doi]
PST - ppublish
SO  - Nihon Ika Daigaku Zasshi. 1992 Oct;59(5):418-27. doi: 10.1272/jnms1923.59.418.